Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.

ABSTRACT: Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) of 1,031 refractory metastatic tumors profiled via whole-exome and transcriptome sequencing. META-PRISM tumors, particularly prostate, bladder, and pancreatic types, displayed the most transformed genomes compared with primary untreated tumors. Standard-of-care resistance biomarkers were identified only in lung and colon cancers-9.6% of META-PRISM tumors, indicating that too few resistance mechanisms have received clinical validation. In contrast, we verified the enrichment of multiple investigational and hypothetical resistance mechanisms in treated compared wit

SUBMITTER: Pradat Y 

PROVIDER: S-EPMC10157368 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature